Teva Pharmaceutical Industries Balance Sheet Health
Financial Health criteria checks 2/6
Teva Pharmaceutical Industries has a total shareholder equity of $7.5B and total debt of $19.6B, which brings its debt-to-equity ratio to 260.4%. Its total assets and total liabilities are $42.8B and $35.2B respectively. Teva Pharmaceutical Industries's EBIT is $3.3B making its interest coverage ratio 3.5. It has cash and short-term investments of $3.0B.
Key information
260.4%
Debt to equity ratio
US$19.64b
Debt
Interest coverage ratio | 3.5x |
Cash | US$2.99b |
Equity | US$7.54b |
Total liabilities | US$35.23b |
Total assets | US$42.77b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: TEVA's short term assets ($12.3B) do not cover its short term liabilities ($13.8B).
Long Term Liabilities: TEVA's short term assets ($12.3B) do not cover its long term liabilities ($21.4B).
Debt to Equity History and Analysis
Debt Level: TEVA's net debt to equity ratio (220.8%) is considered high.
Reducing Debt: TEVA's debt to equity ratio has increased from 180.9% to 260.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable TEVA has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: TEVA is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 19.1% per year.